- Home
- TENX vs NXL Comparison
TENX vs NXL Comparison
Compare TENX & NXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TENX
- NXL
- Stock Information
- Founded
- TENX 1967
- NXL 2010
- Country
- TENX United States
- NXL United States
- Employees
- TENX N/A
- NXL N/A
- Industry
- TENX Biotechnology: Pharmaceutical Preparations
- NXL Medical Specialities
- Sector
- TENX Health Care
- NXL Health Care
- Exchange
- TENX Nasdaq
- NXL Nasdaq
- Market Cap
- TENX 21.6M
- NXL 24.2M
- IPO Year
- TENX N/A
- NXL 2022
- Fundamental
- Price
- TENX $6.06
- NXL $1.29
- Analyst Decision
- TENX Strong Buy
- NXL Strong Buy
- Analyst Count
- TENX 3
- NXL 1
- Target Price
- TENX $16.00
- NXL $5.00
- AVG Volume (30 Days)
- TENX 11.9K
- NXL 89.6K
- Earning Date
- TENX 05-14-2025
- NXL 05-13-2025
- Dividend Yield
- TENX N/A
- NXL N/A
- EPS Growth
- TENX N/A
- NXL N/A
- EPS
- TENX N/A
- NXL N/A
- Revenue
- TENX N/A
- NXL $131,065.00
- Revenue This Year
- TENX N/A
- NXL $79.59
- Revenue Next Year
- TENX N/A
- NXL $334.65
- P/E Ratio
- TENX N/A
- NXL N/A
- Revenue Growth
- TENX N/A
- NXL N/A
- 52 Week Low
- TENX $2.77
- NXL $0.53
- 52 Week High
- TENX $7.89
- NXL $4.49
- Technical
- Relative Strength Index (RSI)
- TENX 55.80
- NXL 45.31
- Support Level
- TENX $5.60
- NXL $1.18
- Resistance Level
- TENX $6.31
- NXL $1.29
- Average True Range (ATR)
- TENX 0.27
- NXL 0.07
- MACD
- TENX -0.01
- NXL 0.03
- Stochastic Oscillator
- TENX 63.31
- NXL 60.00
About TENX Tenax Therapeutics Inc.
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.
About NXL Nexalin Technology Inc.
Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.